Talk:Advanced Cell Therapeutics

Use of term "fraudulent" in lede
I reviewed this new article for DYK. This issue has been nagging, but not enough to make it a factor in the DYK review. It might be a good idea to qualify the use of term "fraudulent" in the lede a bit. It appears the exec(s) were indicted in some jurisdictions, at least the U.S. But had non-judicial regulatory sanctions in others. This may well not be getting all the nuances right. But the point is one word in the lede may be too concise for the situation. ☆ Bri (talk) 20:38, 4 June 2018 (UTC)
 * hm. I added the FDA ref there and made another tweak in these diffs.  Marketing X when it is really Y, and saying X does Z when there is no evidence for that, is pretty much the definition of fraud and when one does that in medicine it is quackery. Jytdog (talk) 19:14, 15 July 2018 (UTC)